Disease · MONDO_0005984
Comparisons in its trials21
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 21
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NAFT-600 vs Placebo: serious adverse events | 1 of 572 | 2 of 287 | 859 | NCT01290341 | Trial comparisons |
| NAFT-600 vs Placebo: serious adverse events | 2 of 571 | 2 of 284 | 855 | NCT01289015 | Trial comparisons |
Test: Ketoconazole Cream 2% vs Reference: Ketoconazole Cream 2%: Secondary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Clinical Cure of Tinea Pedis (Equivalence: Per-Protocol Population) | 97 of 184 | 110 of 191 | 375 | NCT03824912 | Trial comparisons |
Test: Ketoconazole Cream 2% vs Reference: Ketoconazole Cream 2%: Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population) | 89 of 184 | 90 of 191 | 375 | NCT03824912 | Trial comparisons |
Test: Ketoconazole Cream 2% vs Reference: Ketoconazole Cream 2%: Secondary Efficacy Endpoint:The Number of Patients in Each Treatment Group With a Mycological Cure of Tinea Pedis (Equivalence: Per-Protocol Population) | 127 of 184 | 118 of 190 | 374 | NCT03824912 | Trial comparisons |
| Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure | 96 of 185 | 81 of 170 | 355 | NCT03129321 | Trial comparisons |
| Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Mycological Cure | 136 of 185 | 125 of 170 | 355 | NCT03129321 | Trial comparisons |
| Test vs Reference Standard: Proportion of Patients in Each Active Treatment Group Who Are Considered a Clinical Cure (Patient's Total Severity Score Must be ≤ 2 With no Individual Severity Score > 1) | 113 of 185 | 99 of 170 | 355 | NCT03129321 | Trial comparisons |
| NAFT-500 vs Placebo-2wks: serious adverse events | 0 of 166 | 0 of 168 | 334 | NCT00750152 | Trial comparisons |
| Terbinafine vs Placebo: Number of Subjects With Adverse Event | 9 of 146 | 11 of 144 | 290 | NCT01433107 | Trial comparisons |
| Terbinafine vs Placebo: serious adverse events | 0 of 146 | 0 of 144 | 290 | NCT01433107 | Trial comparisons |
| Econazole Nitrate Foam 1% vs Vehicle Foam: serious adverse events | 0 of 130 | 1 of 134 | 264 | NCT01353976 | Trial comparisons |
| Terbinafine vs Placebo: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) | 73 of 115 | 10 of 122 | 237 | NCT01433107 | Trial comparisons |
| Luliconazole Cream 1% vs Vehicle Cream: serious adverse events | 0 of 60 | 0 of 15 | 75 | NCT02767947 | Trial comparisons |
| Tinea Pedis vs Tinea Cruris: serious adverse events | 0 of 15 | 0 of 15 | 30 | NCT02767271 | Trial comparisons |
| Nitric Oxide vs Control: deaths from any cause | 0 of 13 | 0 of 7 | 20 | NCT02871011 | Trial comparisons |
| Nitric Oxide vs Control: serious adverse events | 0 of 13 | 0 of 7 | 20 | NCT02871011 | Trial comparisons |
| Nitric Oxide vs Control: Number of Participants With Complete Cure: Post Treatment (Day 31) | 5 of 8 | 0 of 4 | 12 | NCT02871011 | Trial comparisons |
| Nitric Oxide vs Control: Number of Participants With Therapeutic Failure: Post Treatment (Day 17) | 0 of 8 | 2 of 4 | 12 | NCT02871011 | Trial comparisons |
| Nitric Oxide vs Control: Number of Participants withTherapeutic Failure: Post Treatment Day 31 AND a Post Treatment Clinical Symptom Severity Score (Day 31) of < 8. | 0 of 8 | 1 of 4 | 12 | NCT02871011 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005984/comparisons